Literature DB >> 12453911

Activation of tubular epithelial cells in diabetic nephropathy.

Michael Morcos1, Ahmed A R Sayed, Angelika Bierhaus, Benito Yard, Rüdiger Waldherr, Wolfgang Merz, Ingrid Kloeting, Erwin Schleicher, Stefani Mentz, Randa F Abd el Baki, Hans Tritschler, Michael Kasper, Vedat Schwenger, Andreas Hamann, Klaus A Dugi, Anne-Marie Schmidt, David Stern, Reinhard Ziegler, Hans U Haering, Martin Andrassy, Fokko van der Woude, Peter P Nawroth.   

Abstract

Previous studies have shown that renal function in type 2 diabetes correlates better with tubular changes than with glomerular pathology. Since advanced glycation end products (AGEs; AGE-albumin) and in particular carboxymethyllysine (CML) are known to play a central role in diabetic nephropathy, we studied the activation of nuclear factor kappaB (NF-kappaB) in tubular epithelial cells in vivo and in vitro by AGE-albumin and CML. Urine samples from healthy control subjects (n = 50) and type 2 diabetic patients (n = 100) were collected and tested for excretion of CML and the presence of proximal tubular epithelial cells (pTECs). CML excretion was significantly higher in diabetic patients than in healthy control subjects (P < 0.0001) and correlated with the degree of albuminuria (r = 0.7, P < 0.0001), while there was no correlation between CML excretion and HbA(1c) (r = 0.03, P = 0.76). Urine sediments from 20 of 100 patients contained pTECs, evidenced by cytokeratin 18 positivity, while healthy control subjects (n = 50) showed none (P < 0.0001). Activated NF-kappaB could be detected in the nuclear region of excreted pTECs in 8 of 20 patients with pTECs in the urine sediment (40%). Five of eight NF-kappaBp65 antigen-positive cells stained positive for interleukin-6 (IL-6) antigen (62%), while only one of the NF-kappaB-negative cells showed IL-6 positivity. pTECs in the urine sediment correlated positively with albuminuria (r = 0.57, P < 0.0001) and CML excretion (r = 0.55, P < 0.0001). Immunohistochemistry in diabetic rat kidneys and a human diabetic kidney confirmed strong expression of NF-kappaB in tubular cells. To further prove an AGE/CML-induced NF-kappaB activation in pTECs, NF-kappaB activation was studied in cultured human pTECs by electrophoretic mobility shift assays (EMSAs) and Western blot. Stimulation of NF-kappaB binding activity was dose dependent and was one-half maximal at 250 nmol/l AGE-albumin or CML and time dependent at a maximum of activation after 4 days. Functional relevance of the observed NF-kappaB activation was demonstrated in pTECs transfected with a NF-kappaB-driven luciferase reporter plasmid and was associated with an increased release of IL-6 into the supernatant. The AGE- and CML-dependent activation of NF-kappaBp65 and NF-kappaB-dependent IL-6 expression could be inhibited using the soluble form of the receptor for AGEs (RAGE) (soluble RAGE [sRAGE]), RAGE-specific antibody, or the antioxidant thioctic acid. In addition transcriptional activity and IL-6 release from transfected cells could be inhibited by overexpression of the NF-kappaB-specific inhibitor kappaBalpha. The findings that excreted pTECs demonstrate activated NF-kappaB and IL-6 antigen and that AGE-albumin and CML lead to a perpetuated activation of NF-kappaB in vitro infer that a perpetuated increase in proinflammtory gene products, such as IL-6, plays a role in damaging the renal tubule.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453911     DOI: 10.2337/diabetes.51.12.3532

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  45 in total

1.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

2.  Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.

Authors:  Ligia Petrica; Adrian Vlad; Gheorghe Gluhovschi; Alina Zamfir; Cristina Popescu; Florica Gadalean; Victor Dumitrascu; Daliborca Vlad; Roxana Popescu; Silvia Velciov; Cristina Gluhovschi; Flaviu Bob; Oana Milas; Sorin Ursoniu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  Soluble Receptor for Advanced Glycation End Products Improves Stromal Cell-Derived Factor-1 Activity in Model Diabetic Environments.

Authors:  Melissa Przyborowski Olekson; Renea A Faulknor; Henry C Hsia; Ann Marie Schmidt; François Berthiaume
Journal:  Adv Wound Care (New Rochelle)       Date:  2016-12-01       Impact factor: 4.730

4.  Fluvastatin inhibits angiotensin II-induced nuclear factor kappa B activation in renal tubular epithelial cells through the p38 MAPK pathway.

Authors:  Ping Gao; Xiaoyan Wu; Hua Shui; Ruhan Jia
Journal:  Mol Biol Rep       Date:  2011-09-24       Impact factor: 2.316

5.  Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?

Authors:  Josephine M Forbes; Georgia Soldatos; Merlin C Thomas
Journal:  Clin Biochem Rev       Date:  2005-11

Review 6.  Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Authors:  Andrzej S Krolewski; Tomohito Gohda; Monika A Niewczas
Journal:  Clin Exp Nephrol       Date:  2013-11-12       Impact factor: 2.801

7.  In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs.

Authors:  Angela Cassese; Iolanda Esposito; Francesca Fiory; Alessia P M Barbagallo; Flora Paturzo; Paola Mirra; Luca Ulianich; Ferdinando Giacco; Claudia Iadicicco; Angela Lombardi; Francesco Oriente; Emmanuel Van Obberghen; Francesco Beguinot; Pietro Formisano; Claudia Miele
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

8.  LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats.

Authors:  J L Figarola; S Scott; S Loera; C Tessler; P Chu; L Weiss; J Hardy; S Rahbar
Journal:  Diabetologia       Date:  2003-07-05       Impact factor: 10.122

Review 9.  Redox control of renal function and hypertension.

Authors:  Ravi Nistala; Adam Whaley-Connell; James R Sowers
Journal:  Antioxid Redox Signal       Date:  2008-12       Impact factor: 8.401

10.  Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice.

Authors:  Riyaz Mohamed; Calpurnia Jayakumar; Punithavathi V Ranganathan; Vadivel Ganapathy; Ganesan Ramesh
Journal:  Am J Pathol       Date:  2012-10-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.